MarketCap
Facebook
X
Telegram
ContraFect Corporation Operating Income | CFRX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income ContraFect Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -64.6 M | -47.3 M | -34.2 M | -27.9 M | -31.1 M | -26.6 M | -33.5 M | -25.1 M | -16.9 M | -19.3 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -16.9 M | -64.6 M | -32.6 M |
Quarterly Operating Income ContraFect Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.68 M | -7.98 M | -8.86 M | - | -21.9 M | -20 M | -16 M | - | -11.7 M | -10.7 M | -10.8 M | - | -7.31 M | -8.16 M | -8.06 M | -6.47 M | -7.63 M | -7.41 M | -6.36 M | -8.84 M | -7.8 M | -7.5 M | -6.98 M | -7.4 M | -6.74 M | -6.08 M | -6.35 M | -6.71 M | -7.89 M | -9.78 M | -9.15 M | - | -5.72 M | -7.16 M | -4.7 M | - | -4.64 M | -2.68 M | -4.79 M | - | -3.57 M | -3.9 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.68 M | -21.9 M | -8.18 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
-121 M | $ 1.31 | 6.5 % | $ 166 M |  Schweiz |
 |
ADMA Biologics
ADMA
|
191 M | $ 9.7 | 3.21 % | $ 2.31 B |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-57.1 M | $ 27.89 | 0.3 % | $ 4.23 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 13.3 | 1.06 % | $ 364 M |  Israel |
 |
AbbVie
ABBV
|
15.1 B | $ 265.08 | 0.02 % | $ 469 B | USA |
 |
Axsome Therapeutics
AXSM
|
-167 M | $ 193.45 | 0.24 % | $ 9.62 B | USA |
 |
Aytu BioScience
AYTU
|
-8.32 M | $ 2.28 | 2.24 % | $ 28.1 M | USA |
 |
Adagene
ADAG
|
-21.4 M | $ 2.97 | 0.62 % | $ 175 M |  China |
 |
Abeona Therapeutics
ABEO
|
-89.4 M | $ 5.53 | 2.65 % | $ 293 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
-7.8 M | $ 4.04 | 0.24 % | $ 2.7 M | USA |
 |
Evelo Biosciences
EVLO
|
-108 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
409 M | $ 62.21 | 0.06 % | $ 11.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-38.2 M | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
-9.95 M | $ 2.16 | 0.45 % | $ 3.56 M | Israel |
 |
Catalyst Biosciences
CBIO
|
11.5 M | $ 14.19 | 1.17 % | $ 1.27 B | USA |
 |
Amryt Pharma plc
AMYT
|
-38.6 M | - | - | $ 621 M |  Britain |
 |
C4 Therapeutics
CCCC
|
-115 M | $ 3.08 | 0.3 % | $ 255 M | USA |
 |
Codexis
CDXS
|
-41.7 M | $ 1.38 | 0.72 % | $ 120 M | USA |
 |
Allakos
ALLK
|
-122 M | - | - | $ 28.6 M | USA |
 |
Cerus Corporation
CERS
|
-8.68 M | $ 2.6 | 4.3 % | $ 496 M | USA |
 |
Coherus BioSciences
CHRS
|
-181 M | $ 1.26 | 1.48 % | $ 148 M | USA |
 |
Celldex Therapeutics
CLDX
|
-287 M | $ 31.12 | 0.28 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-11.5 M | $ 4.04 | 4.94 % | $ 49.3 M | Israel |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 12.31 | 0.12 % | $ 3.68 B | Canada |
 |
Aclaris Therapeutics
ACRS
|
-76.4 M | $ 5.26 | 2.69 % | $ 645 M | USA |
 |
Clovis Oncology
CLVS
|
-52.7 M | - | -7.23 % | $ 13 M | USA |
 |
Cocrystal Pharma
COCP
|
-9.02 M | $ 1.19 | 1.26 % | $ 13.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
60.8 M | $ 22.45 | 1.05 % | $ 711 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
44.8 M | $ 112.94 | 3.29 % | $ 11.7 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-85.3 M | $ 7.74 | 0.19 % | $ 103 M | USA |
 |
Cardiff Oncology
CRDF
|
-49 M | $ 1.31 | 0.74 % | $ 87.6 M | USA |
 |
Curis
CRIS
|
-5.71 M | $ 0.95 | 0.98 % | $ 12.5 M | USA |
 |
CorMedix
CRMD
|
150 M | $ 7.69 | 0.06 % | $ 554 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-665 M | $ 55.76 | 1.2 % | $ 5.01 B | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
-43 M | $ 12.54 | 8.21 % | $ 990 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-77.5 M | - | - | $ 401 M | USA |
 |
Cue Biopharma
CUE
|
-26.6 M | $ 31.71 | 2.62 % | $ 3 B | USA |
 |
CEL-SCI Corporation
CVM
|
-24.8 M | $ 1.68 | 0.59 % | $ 13.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
-612 M | $ 65.81 | 0.04 % | $ 7.9 M | USA |
 |
Axon Enterprise
AXON
|
-62.1 M | $ 450.61 | 1.61 % | $ 35.2 B | USA |
 |
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
-34.4 M | $ 7.56 | 7.16 % | $ 355 M | USA |
 |
Denali Therapeutics
DNLI
|
-555 M | $ 20.46 | 5.52 % | $ 3.53 B | USA |
 |
Precision BioSciences
DTIL
|
-52.1 M | $ 6.36 | 10.62 % | $ 81.6 M | USA |
 |
Dyadic International
DYAI
|
-7.19 M | $ 0.41 | 3.72 % | $ 14.8 M | USA |
 |
Editas Medicine
EDIT
|
-160 M | $ 2.69 | 0.17 % | $ 239 M | USA |
 |
Edesa Biotech
EDSA
|
-7.91 M | $ 3.97 | 1.46 % | $ 22.5 M | USA |